MaxCyte Director Executes Options, Sells Shares
Company Announcements

MaxCyte Director Executes Options, Sells Shares

MaxCyte (MXCT) has released an update.

MaxCyte Inc.’s Non-Executive Director, Stanley Erck, has exercised options and sold shares, representing a significant transaction in the company’s stock. Between September 3 and 4, 2024, Erck exercised options for 47,689 shares of MaxCyte’s common stock and sold them at prices ranging from $3.90 to $4.30. Following these transactions, Erck’s holdings have adjusted to 247,751 shares and 371,879 options, signaling noteworthy insider activity in the firm’s financial dynamics.

For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskBlackRock Ups Stake in MaxCyte to 9.75%
TheFlyMaxCyte, Kamau Therapeutics enter strategic platform license agreement
TipRanks UK Auto-Generated NewsdeskMaxCyte Partners with Kamau Therapeutics to Advance Gene Therapies
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App